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This retrospective study analyzed the impact of directional donor-recipient human leukocyte antigen (HLA)
disparity using allele-level typing at HLA-A, -B, -C, and -DRB1 in 79 adults with acute myeloid leukemia (AML)
who received single-unit umbilical cord blood (UCB) transplant at a single institution. With extended high-
resolution HLA typing, the donor-recipient compatibility ranged from 2/8 to 8/8. HLA disparity showed no
negative impact on nonrelapse mortality (NRM), graft-versus-host (GVH) disease or engraftment. Considering
disparities in the GVH direction, the 5-year cumulative incidence of relapse was 44% and 22% for patients
receiving an UCB unit matched  6/8 and < 6/8, respectively (P ¼ .04). In multivariable analysis, a higher HLA
disparity in the GVH direction using extended high-resolution typing (Risk ratio [RR] 2.8; 95% conﬁdence
interval [CI], 1.5 to 5.1; P ¼ .0009) and ﬁrst complete remission at time of transplantation (RR 2.1; 95% CI, 1.2 to
3.8; P ¼ .01) were the only variables signiﬁcantly associated with an improved disease-free survival. In
conclusion, we found that in adults with AML undergoing single-unit UCBT, an increased number of HLA
disparities at allele-level typing improved disease-free survival by decreasing the relapse rate without a
negative effect on NRM.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION outcomes of a series of adults with acute myeloid leukemia
One intrinsic advantage of umbilical cord blood (UCB)
over other stem cell sources for allogeneic stem cell trans-
plantation is the ability to tolerate greater degrees of human
leukocyte antigen (HLA) disparity. However, the impact of
donor-recipient HLA mismatch on umbilical cord blood
transplantation (UCBT) outcomes is still not well established,
particularly in adults.
Most registry-based studies that included a majority of
pediatric population and a variety of diseases have reported
an increased nonrelapse mortality (NRM) rate with HLA
disparity considering HLA-A and -B by low-resolution and
DRB1 by high-resolution techniques [1-4], although this
negative effect may be restricted to mismatches in the
rejection direction [5]. However, the impact on outcomes of
HLA disparity seems different in the adults, with no increase
in NRM and a possible beneﬁt in relapse [6]. Although closer
match at allelic level has consistently shown improved out-
comes after unrelated bonemarrow or peripheral blood stem
cell transplantation [7], very few studies have evaluated the
importance of extended HLA typing at allele level in UCBT.
We hypothesized that a higher degree of HLA mismatch
could enhance the graft-versus-leukemia (GVL) effect,
decreasing the relapse risk and potentially affecting other
outcomes. We, therefore, analyzed the short- and long-termedgments on page 109.
equests: Jaime Sanz, MD, Hospital Uni-
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13.10.016(AML) who received UCBT from unrelated donors at a single
institution, focusing on the impact on outcomes of donor-
recipient HLA match, using extended allele-level typing.
PATIENTS AND METHODS
Eligibility Criteria
Between June 2000 and December 2012, 79 consecutive adult patients
with AML underwent myeloablative UCBT from unrelated donors at our
institution. Patients were eligible for enrollment if they met the following
criteria: (1) high-risk AML, deﬁned by either high-risk cytogenetics or poor
prognosis gene markers, more than 1 cycle to achieve complete remission
(CR), or disease status beyond ﬁrst CR; and (2) no suitable related donor
(HLA-identical or 1-antigenemismatched). From 2005, patients were
included in 2 subsequent prospective trials: TSCU-GETH2005 (21 patients)
and TSCU-GETH/GITMO2008 (42 patients). The institutional review board
approved the protocol and written informed consent was obtained from all
patients according to the Declaration of Helsinki. TSCU-GETH/GITMO2008
clinical trial was registered on the EudraCT with code 2008-000927-24.
The treatment plans, including of graft selection, conditioning regimen,
immune suppression, and supportive care have been reported in detail
previously [8,9], and are summarized below.
Umbilical Cord Blood Unit Selection and Management
The search of UCB units was conducted by the Spanish Registry of Bone
Marrow Donors (Registro Español de Donantes de Médula Ósea). Graft se-
lection algorithm required UCB  4/6 HLA matched with the recipient (HLA
class I antigens [A and B] considering the antigen level and class II antigens
[DRB1] considering allele-level resolution DNA typing). Minimum total
nucleated cell (TNC) and CD34þ cell counts from the information provided
by the different UCB banks were required. Minimum cell dose criteria
changed over time. A TNC dose  1.5  107/kg recipient’s body weight was
required until 2005, whereas TNC  2  107/kg and CD34þ cell dose  1 
105/kg recipient’s body weight were required in 2006 and 2007. From 2008
to present, minimum cell dose criteria considered total cell dose of the UCB
units without taking into account recipient’s body weight as follows: TNC >Transplantation.
Table 1
Characteristics of Patients with AML Undergoing UCBT
Characteristic n
No. of patients 79
Age, median (range), yr 37 (16-55)
Gender, n (%)
Male 50 (63)
Female 29 (37)
Weight, median (range) kg 71 (37-112)
Disease status at transplantation
First complete remission 46 (58)
Second complete remission 11 (14)
More advanced phase 22 (28)
Diagnosis
De novo 70 (89)
Therapy- or MDS-related secondary AML 9 (11)
Cytogenetics*
Favorable 2 (3)
Intermediate 42 (53)
Poor 24 (30)
Unknown 11 (14)
Previous autologous transplantation 7 (9)y
Cytomegalovirus serologic status before transplantation
Positive 60 (76)
Negative 19 (24)
AML indicates acute myeloid leukemia; UCBT, umbilical cord blood trans-
plantation; MDS, myelodysplastic syndrome.
Percentages may total 100 because of rounding. Data presented are n (%),
unless otherwise indicated.
* Cytogenetic risk according to European Leukemia Net classiﬁcation.
y One patient underwent 2 autologous transplantations.
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Conditioning Regimen
Two subsequent myeloablative conditioning regimens were used, all
based on the combination of thiotepa, busulfan, cyclophospamide or ﬂu-
darabine, and antithymocyte globulin (ATG). Until March 2005, 16 patients
received thiotepa (10 mg/kg), busulfan (12 mg/kg orally in 8 patients or 9.6
mg/kg i.v. in 8 patients), cyclophosphamide (120 mg/kg) and ATG (Lym-
phoglobuline, Merieux, Lyon, France; 60 mg/kg in the ﬁrst 6 patients or
Thymoglobulin, Genzyme Transplant, Cambridge, MA; 8 mg/kg in the
remaining 10 patients). From March 2005, the remaining 63 patients
received thiotepa (10 mg/kg), i.v. busulfan as a single dose (9.6 mg/kg),
ﬂudarabine (150 mg/m2), and ATG (Thymoglobulin 8 mg/kg in the ﬁrst 21
patients and 6 mg/kg in the remaining 42 patients).
Graft-versus-host-disease Prophylaxis and Treatment
All patients received cyclosporine 1.5 mg/kg/12 hours i.v., followed by 3
to 5 mg/kg/12 hours orally when oral intake was possible, with slow
tapering starting between day þ90 and þ180 and discontinuation on
dayþ180, or before if feasible. Cyclosporine was combined with long-course
prednisone in the ﬁrst 38 patients (.5 mg/kg/day on days þ7 to þ14, 1 mg/
kg/day on days þ14 to þ28, with slow tapering until discontinuation on
day þ180), micofenolate-mofetil (15 mg/kg/12 hours until day þ28) in the
following 26 patients, or a short course of prednisone in the last 15 patients
(1 mg/kg/day on days þ14 to þ28). Patients developing acute graft-versus-
host disease (GVHD) received high-dose methylprednisolone as initial
therapy (20 mg/kg/day; halving the dose every 3 days until reaching 1 mg/
kg/day, and then gradually tapered), followed by ATG in refractory cases.
Chronic GVHD was treated with prednisone 1 mg/kg/day.
HLA Typing
For conﬁrmation purposes, all patients and UCB units were HLA typed in
our laboratory (D.P.). High-resolution typing was performed for HLA-A, -B,
-C, and DRB1 in all patient and donor pairs as previously described [10].
High-resolution (allele level) and low-resolution (serologic or antigen level)
HLA matching were considered in the analysis of clinical outcomes. Low-
resolution disparities involved conversion of the DNA-based typing to its
lower level serologic equivalent, by collapsing the 4-digit typing result back
to its ﬁrst 2 digits. Directional mismatches were considered in the analysis.
Mismatch in the graft-versus-host (GVH) direction was deﬁned in homo-
zygous donors at an HLA locus when the recipient shared 1 HLA antigen
with the donor. Mismatch in the host-versus-graft (HVG) direction was
deﬁned in homozygous recipients at an HLA locus when the donor shared 1
HLA antigen with the recipient. Mismatches at homozygous alleles were
considered single mismatches.
Deﬁnitions
Treatment outcomes were assessed according to the revised criteria by
Cheson et al. [11]. Myeloid engraftment was deﬁned as an absolute
neutrophil count (ANC) of .5  109/L or greater on 3 consecutive days.
Platelet engraftment was deﬁned as a platelet count of 20  109/L or higher,
without transfusion support, for 7 consecutive days. Patients who survived
more than 28 days after transplantation and who failed to achieve myeloid
engraftment were considered graft failures. Time to myeloid or platelet
engraftment was deﬁned as the time required to reach the ﬁrst day of
engraftment. Secondary graft failure was deﬁned as the loss of the
engraftment. Acute and chronic GVHD were deﬁned and graded according
to standard criteria [12-14]. Killer cell immunoglobulin-like receptor (KIR)-
ligand compatibility was deﬁned as described byWillemze et al. [15]. Brieﬂy,
KIR-ligand compatibility in the GVH direction was determined according to
whether or not they expressed HLA-C group 1 or 2, HLA-Bw4, or HLA-A3/-
A11. NRM was deﬁned as death from any cause without evidence of
relapse. Disease-free survival was deﬁned as survival from the time of
transplantation without evidence of disease relapse.
Statistical Analysis
The probabilities of engraftment, NRM, GVHD, and relapse were esti-
mated by the cumulative incidence method (marginal probability) [16,17].
For cumulative incidence analyses of engraftment, GVHD, and relapse, death
in CR was considered as a competing cause of failure, whereas relapse was
the competing event for NRM. Unadjusted time-to-event analyses were
performed using the Kaplan-Meier estimate [18], and, for comparisons, the
log-rank tests [19]. Disease-free survival was calculated from the date of
UCBT. In the analysis of leukemia-free survival (LFS), relapse, or death in CR,
whichever occurred ﬁrst, was considered an uncensored event. The follow-
up of the patients was updated on December 1, 2012. A Cox proportional
hazards model [20] or the Fine and Gray method for competing events [21]were used for multivariable analysis using variables with a P value < .10 for
each endpoint. The variables considered for prognostic factor analysis were
age, gender, recipient weight, recipient CMV serology, disease status at
transplantation, HLA compatibility considering HLA-A, -B, -C, and DRB1 by
high- and low-resolution typing, ABO blood group mismatch, KIR-ligand
incompatibility, conditioning regimen, GVHD prophylaxis, and TNC and
CD34þ cells before freezing and infused. Continuous variables were
dichotomized at the most discriminative cutoff point for each outcome. The
slight modiﬁcations in the conditioning regimen and GVHD prophylaxis
performed over the years did not have an impact on any outcome and.
Therefore, subgroup analysis was not performed, although these variables
were included in the multivariable analysis. Statistical analyses were con-
ducted using R version 2.12.2 (The CRAN project) with packages, survival
v2.37-4, rms 3.6-3, prodlim v1.3.3, and cmprsk v2.2-4 [22].RESULTS
Patient, Graft, and Transplantation Characteristics
Patient characteristics are shown in Table 1. Brieﬂy, me-
dian age was 37 years (range, 16 to 55) and 55 patients (72%)
were in CR1 or CR2.
Graft and transplantation characteristics are shown in
Table 2. Brieﬂy, 26 (33%) males received a graft from a female
donor and KIR-ligand mismatch was present in 28 (35%)
patients.Donor-recipient HLA Matching
Table 3 shows the number of HLA disparities between
donors and recipients using the standard HLA match criteria
used for unit selection, as well as the extended allele-level
typing at HLA-A, -B, -C, and DRB1. The number of HLA dis-
parities was considered in both GVH and HVG direction.
With the standard criteria, 6 patients (8%) received a fully
matched 6/6 UCB unit whereas 19 patients (24%) and 54
patients (68%) received a 5/6 and 4/6 matched graft,
respectively. With extended high-resolution HLA typing, the
donor-recipient compatibility ranged from 2/8 to 8/8. Ten
donors had at least 1 homozygous allele resulting in a unique
vector in the GVH direction, whereas 7 patients had at least 1
Table 2
Graft and Transplantation Characteristics
Characteristic n (%)
Donor-recipient sex match
Male-male 24 (30)
Male-female 13 (16)
Female-male 26 (33)
Female-female 16 (20)
KIR-ligand incompatibility in graft-versus-host direction
Yes 28 (35)
No 51 (65)
Conditioning regimen
TT þ BU þ CY þ ATG 16 (20)
TT þ BU þ FLU þ ATG 63 (80)
Graft-versus-host disease prophylaxis
Cyclosporine A þ prednisone 53 (67)
Cyclosporine A þ MMF 26 (33)
No. of nucleated cells before freezing,  107/kg
Median 3
Range 1.4-6.8
No. of nucleated cells infused,  107/kg
Median 2.4
Range 1.0-4.9
No. of CD34þ cells before freezing,  105/kg
Median 1.6
Range .2-4.1
No. of CD34þcells infused,  105/kg
Median 1.3
Range .1-6.1
TT indicates thiotepa; BU, busulfan; CY, cyclophosphamide; FLU, ﬂudar-
abine; ATG, antithymocyte globulin; MMF, micofenolate-mofetil.
Percentages may total 100 because of rounding. Data presented are n (%),
unless otherwise indicated.
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Engraftment and GVHD
The cumulative incidence of myeloid engraftment at 57
days was 95% (95% conﬁdence interval [CI], 89 to 99) at a
median time to neutrophil recovery of 20 days (range, 11 to
57). The cumulative incidence of platelet engraftment at 180
days was 77% (95% CI, 68% to 87%) at a median time to
platelet recovery of 47 days (range, 23 to 138).
The cumulative incidence of acute GVHD at 100 days grade
II to IVand III to IVwas32% (95%CI, 22% to42%)and17% (95%CI,
8% to 25%), respectively. The cumulative incidence of chronic
extensive GVHD at 3 years was 38% (95% CI, 26% to 50%).
HLA disparity had no signiﬁcant impact in multivariable
analysis on myeloid and platelet engraftment, or acute and
chronic GVHD.
Nonrelapse Mortality
Thirty-one patients died without relapse at a median of
181 days (range, 19 to 2535). The 5-year cumulative inci-
dence of NRM for the entire cohort was 35% (95% CI, 25% toTable 3
Number of HLA Mismatches between Donor and Recipient
Allele level HLA match for HLA-A, -B, -C and DRB1, n
Bidirectional Mismatches Mismatches in the Gr
Direction
2/8 3/8 4/8 5/8 6/8 7/8 8/8 2/8 3/8 4/8
Standard HLA match*
6/6 0 0 0 0 2 2 2 0 0 0
5/6 0 0 2 5 5 7 0 0 0 2
4/6 2 4 13 33 2 0 0 2 3 12
Total 2 4 15 38 9 9 2 2 3 14
* HLA-A and -B at the antigen level and DRB1 at the allele level.46%). HLA disparity had no signiﬁcant impact on NRM. In
multivariate analysis TNC  2.4  107/kg was the only vari-
able signiﬁcantly associated with a higher NRM (relative risk
[RR], 2.7; 95% CI, 1.3 to 5.9; P ¼ .009).
Impact of HLA Mismatch on Relapse
Overall, 21 patients relapsed at a median time of 202 days
(range, 32 to 1372). The 5-year cumulative incidence of
relapse of the entire cohort was 28% (95% CI, 18% to 39%). For
patients who underwent transplantation in CR, cumulative
incidence of relapse was 24% compared with 41% for patients
who underwent transplantation while in relapse (P ¼ .08).
With extended high-resolution HLA typing, bidirectional
mismatches showed no impact on the risk of relapse; how-
ever, the 5-year cumulative incidence of relapse was 44% and
22% for patients receiving an UCB unit matched  6/8 and <
6/8, respectively (P ¼ .04) (Figure 1).
In multivariable analysis, a higher HLA disparity in the
GVH direction using extended high-resolution typing (RR, .4;
95% CI, .2 to .9; P ¼ .0004) and CR at time of transplantation
(RR, .4; 95% CI, .2 to .9; P ¼ .02) were the only variables
signiﬁcantly associated with a reduced risk of relapse.
Leukemia-free Survival
After a median follow-up of 66 months (range, 21 to 132)
for surviving patients, 27 patients remained alive and disease
free at last follow-up. The 5-year LFS for the entire cohort
was 35% (95% CI, 23% to 46%). For patients who underwent
transplantation in ﬁrst CR, LFS was 41%, compared with 25%
for patients who underwent transplantation in more
advanced phases of the disease (P ¼ .04).
Considering standard bidirectional HLA typing, the 5-year
LFS was 40%, 26%, and 17% for patients who underwent
transplantation with a 4/6, 5/6, and 6/6 UCB unit, respec-
tively (P ¼ .04). With standard HLA typing and considering
mismatches in the GVH direction, the 5-year LFS was 45%,
21%, and 14% for patients who underwent transplantation
with a 4/6, 5/6, and 6/6 UCB unit, respectively (P ¼ .03).
With extended high-resolution HLA typing, bidirectional
incompatibilities showed no impact on LFS, but considering
mismatches in the GVH direction, the 5-year LFSwas 45% and
10% for patients receiving an UCB unit matched 2 to 5/8 and 6
to 8/8, respectively (P ¼ .003) (Figure 2).
In multivariable analysis, a higher HLA disparity in the
GVH direction using extended high-resolution typing (RR,
2.8; 95% CI, 1.5 to 5.1; P ¼ .0009) and CR1 at time of trans-
plantation (RR, 2.1; 95% CI, 1.2 to 3.8; P ¼ .01) were the only
variables signiﬁcantly associated with an improved LFS.
DISCUSSION
This study shows that a higher donor-recipient HLA
disparity in myeloablative single-unit UCBT for adults withaft-versus-hosty Mismatches in the Host-versus-graftz
Direction
5/8 6/8 7/8 8/8 2/8 3/8 4/8 5/8 6/8 7/8 8/8
0 1 3 2 0 0 0 0 2 2 2
5 5 7 0 0 0 2 5 4 7 1
31 3 2 1 1 3 14 30 5 1 0
36 9 12 3 1 3 16 35 11 10 3
Figure 1. Cumulative incidence of relapse after UCBT according to the number
of HLA disparities in the GVH direction.
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GVL effect, which translates to a beneﬁt on long-term LFS.
We could also identify donor-recipient pairs with a high
number of discrepancies by extended high-resolution HLA
typing without an evident deleterious effect. A separate
analysis of HLA disparity according to GVH and HVG direc-
tion improved the predictive value on relapse rate. These
data may provide clinically useful information for a better
selection of cord blood units in adults with poor-risk AML.
The number of patients and events in this study was
smaller than in registry-based studies and did not allow an
analysis of the impact of speciﬁc HLA disparities. Results
should, therefore, be interpreted with caution. However, this
retrospective study included a series of adults with AML
treatedwith a homogenous strategy of single-unit UCBTafter
busulfan-based myeloablative conditioning regimen at a
single institution. Of note, most patients were included in 2
subsequent prospective trials (TSCU-GETH2005 and TSCU-
GETH/GITMO2008).
With extended high-resolution typing, we identiﬁed a
signiﬁcant proportion of patients that received highlyFigure 2. Kaplan-Meier estimate of leukemia-free survival after UCBT ac-
cording to the number of HLA disparities in the GVH direction.mismatched units. In fact, 70% of the donor-recipient pairs
had 3 or more disparities at the allelic level. Compared to the
standard HLA typing criteria, directional high-resolution
typing was able to further discriminate disparities. For
example, UCB units matched 4/6 with standard criteria had
disparities that were reclassiﬁed ranging from 2/8 to 8/8 in
the GVH direction at high resolution.
Our study showed no negative impact of HLA disparity on
NRM, GVHD, or engraftment, whereas TNC content was the
only variable associated with the risk of NRM. In contrast to
pediatric patients, HLA disparity in adults has never shown a
negative impact on NRM in large registry-based studies
[6,23,24]. The different outcome in children compared with
adults may be explained, at least in part, by the important
differences in cell dose between these populations. Another
important factor to consider is the importance of mismatch
direction on outcomes. However, only few registry-based
studies have evaluated its impact by serologic data with
inconsistent results, maybe because of the heterogeneity of
the population. Some studies have suggested a deleterious
effect on engraftment with mismatches in the HVG direction
[5,25], whereas others found an opposite effect [26]. UCBT
performed with mismatches in the GVH direction had out-
comes that were similar to those that were fully matched
[5,25], but this effect was restricted to children in 1 of the
studies [25]. No mismatch category has been previously
associated with relapse.
We observed an impressive reduction in risk of relapse,
suggesting an enhanced GVL effect, for patients who un-
derwent transplantation with UCB units with a higher HLA
disparity in the GVH direction. This observation was made in
the context of a very high-risk population and a speciﬁc
highly immunosuppressive treatment platform. Future
studies are needed to determine whether this ﬁnding is true
for all or only speciﬁc scenarios. In this regard, previous
registry-based studies from Eurocord [27] and the Japanese
Society for Hematopoietic Cell Transplantation group [6]
have also found that UCBTs with a higher HLA disparity
had a lower probability of relapse. However, we could not see
any favorable effect of KIR-ligand incompatibility in the
graft-versus-host direction as previously described [15]. A
reduced relapse rate, together with the lack of a negative
impact on NRM, translated into improved LFS after UCBT
performed with more mismatched units in the GVH direc-
tion. To our knowledge, this has not been previously re-
ported, maybe because of the fact that this was this was the
ﬁrst disease-speciﬁc analysis of an adult-restricted cohort
evaluating the impact directional HLA mismatches by high-
resolution typing.
In conclusion, we found that in adults with AML under-
going single-unit UCBT with thiotepa, busulfan, ﬂudarabine,
and ATG, UCB units with high number of discrepancies seem
acceptable for transplantation. In fact, an increased number
of HLA disparities using allele-level typing improved disease-
free survival by decreasing the relapse without increasing
mortality rate. Whether these ﬁndings will apply in other
settings, such as double-unit UCBT or using reduced-
intensity conditioning, is unknown and should be further
investigated. Further studies addressing the potential allor-
eactivity and GVL effect of HLA disparity are warranted.
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